Stuttgart, Germany – 24th June 2015 – the unique advantages of the CCM therapy and its encouraging outcomes were presented during EHRA EUROPACE Cardiostim to professionals from around the globe. The CCM therapy has demonstrated its safety and efficacy through a number of randomized clinical trials. The results were displayed at two poster sessions and one Symposia:

Monday, 22 June 2015:

  • Dr. Kuschyk – Poster Presentation (P583) “Cardiac Contractility Modulation with the Optimizer IVs system in patients with symptomatic heart failure despite optimal medical therapy and cardiac resynchronization”.
  • Dr. Kuschyk – Poster Presentation (P865) “The subcutaneous implantable cardioverter-defibrillator: first single-center experience with concomitant implantable pulse generators”.

Tuesday, 23 June 2015:

  • Prof. Hindricks – Scientific talk on CCM “Cardiac contractility modulation ready for broad use”.

About the Optimizer and CCM Therapy

The Optimizer IVs device delivers the CCM therapy. It has been successfully launched in Europe and is available in cardiology centers in various countries. The CCM therapy has been implanted in over 2500 patients to date and is the only device therapy available for patients with narrow QRS complex. Impulse Dynamics has completed a vast number of clinical studies, including several randomized controlled trials. The results have been published in over 60 publications in leading medical journals. The Optimizer system is limited to Investigational use only in the United States.

About Impulse Dynamics

Impulse Dynamics N.V. is focused on the development of electrical therapies for the treatment of chronic heart failure. As a global leader in cardiac medical innovation, Impulse Dynamics has operations in the US, Europe, Asia and Australia. For more information please visit www.impulse-dynamics.com.

Impulse Dynamics is a member of the Hobart Group, a medical device portfolio that accelerates ideas, develops and commercializes medical technologies targeting top healthcare markets with significant unmet needs. The growing portfolio of companies covers the areas of cardiology, diabetes, oncology, neurology and rehabilitation. Together, Hobart Group companies employ over 200 scientists, engineers, regulatory and business experts across four continents, and benefit from the group’s clinical expertise and extensive regulatory and international market knowledge across Europe, the US and Asia. For more information please visit www.hobart-group.com.